Option Care Health (OPCH) Rockets as CD&R, McKesson Table 37% Premium Bid
Option Care Health (OPCH) surged 33% to $31.11 after announcing a $5.8B acquisition by CD&R and McKesson at a 37% premium. The deal, expected to close in 2027, values OPCH at $32.05 per share. The company will delist from Nasdaq. Hedge fund holdings fell 42% QoQ despite more funds establishing positions. Q3 earnings, due Nov 4, 2026, will not include guidance.
How this was made
The 30-second read
Why it matters
The deal creates a combined platform for home and ambulatory infusion, expanding patient access and potentially improving margins.
Market read
The announcement triggered a 33% intraday rally in OPCH and signals strategic expansion for McKesson in specialty infusion services.
What to watch
Regulatory approval timelines and potential antitrust scrutiny could delay closing.
Background
Option Care Health provides infusion therapy services; CD&R is a private‑equity firm; McKesson is a major health‑care distributor.
Ticker impact
Option Care Health announced a definitive agreement to be acquired by CD&R and McKesson at a 37% premium, sending the stock up 33% on the day.
upward pressure as the market prices in the acquisition premium
First‑report of a $5.8 B deal with a large premium; the stock jumped 33% on the news.
McKesson is a 49% partner in the consortium acquiring Option Care Health for $5.8 B.
slight upside as investors view the strategic expansion positively
Deal adds a new business line; impact on McKesson’s share price is secondary to the primary target.
Market effects
Consolidation in the infusion‑therapy and specialty‑care sector may spur further M&A activity.
U.S. healthcare services market sees a notable transaction, modestly affecting related peers.
Large‑scale health‑care deal highlights continued private‑equity involvement in U.S. biotech.
Counterpoint
The premium may be excessive; integration risks could pressure post‑close performance.
Key entities
- companyOption Care Health
Listed infusion‑therapy provider being acquired.
- private_equityClayson, Dubilier & Rice LLC
Lead private‑equity sponsor acquiring 51% stake.
- companyMcKesson Corp.
Health‑care distributor acquiring 49% stake.
